Citius Oncology, the oncology arm of Citius Pharmaceuticals, will exhibit at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida, from December 6 to 9, 2025. The company’s booth, #265, will focus on LYMPHIR, its FDA‑approved immunotherapy for relapsed or refractory cutaneous T‑cell lymphoma (CTCL).
LYMPHIR, a purified reformulation of denileukin diftitox, received FDA approval on August 7, 2024, for adults with Stage I‑III CTCL who have received at least one prior systemic therapy. The approval was based on the Phase 3 Study 302 trial and positions LYMPHIR as the first novel targeted systemic therapy for this rare disease since 2018. The U.S. addressable market for LYMPHIR is estimated to exceed $400 million and is expected to grow as the drug expands into earlier lines of therapy.
The ASH exhibit is a strategic lever in Citius Oncology’s broader launch plan. By meeting hematology clinicians, researchers, and the oncology community in person, the company aims to build awareness, secure prescriber interest, and accelerate market penetration ahead of the Q4 2025 commercial launch. The event also provides an opportunity to demonstrate LYMPHIR’s clinical profile, discuss reimbursement pathways—including the J‑code (J9161) effective April 1, 2025—and gather real‑world feedback that can inform post‑launch commercialization strategies.
Citius Oncology’s commercial strategy for LYMPHIR hinges on a strong launch in the fourth quarter of 2025. The company has secured a J‑code and is preparing a pricing and reimbursement framework that aligns with the drug’s $400 million+ market potential. Competitive analysis shows that LYMPHIR is the only CTCL therapy targeting the interleukin‑2 receptor on malignant T‑cells and regulatory T cells, giving it a unique mechanism of action that could translate into a differentiated market position. The company’s focus on early engagement at ASH is intended to cement prescriber confidence and drive early uptake in a niche but high‑need patient population.
Leonard Mazur, Chairman and CEO of Citius Oncology, said the company is “excited to showcase LYMPHIR at ASH 2025 and to engage with CTCL stakeholders about how our therapy can fill an unmet need.” He added that the company’s launch plan is built on a foundation of strong clinical evidence, a clear reimbursement strategy, and a dedicated commercial team ready to support prescribers and patients as LYMPHIR enters the market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.